Every DEF 14A that Klotho Neurosciences, Inc. (KLTO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLTO filings page.
Greenland Mines Ltd is asking stockholders to approve flexibility for one or more reverse stock splits of its common stock between 1-for-2 and up to an aggregate 1-for-60, plus the ability to adjourn the special meeting to solicit more votes if needed.
The board’s main goal is to help the share price meet Nasdaq’s $1.00 minimum bid requirement for continued listing on The Nasdaq Capital Market. A reverse split would reduce shares outstanding but keep each investor’s ownership percentage essentially the same, aside from rounding up fractional shares.
As of April 23, 2026, the record date, 121,238,660 common shares were outstanding and eligible to vote. The meeting will be held virtually on June 18, 2026, and default proxies will vote in favor of both proposals unless holders give different instructions.
Klotho Neurosciences, Inc. has amended and restated its definitive proxy to change the record and special meeting dates and to seek stockholder approval for several capital actions. The February 17, 2026 virtual Special Meeting will ask investors to approve a reverse stock split of common stock at a ratio between one-for-2 and one-for-50, at the Board’s discretion, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price and potentially broaden institutional interest. Stockholders will also vote on increasing the reserve under the 2024 Equity Incentive Plan to 10,000,000 shares of common stock and on a proposal allowing adjournment of the meeting to solicit additional proxies if needed. As of January 15, 2026, the company had 73,536,722 common shares outstanding, and directors and executive officers as a group beneficially owned 7,303,632 shares.
Klotho Neurosciences, Inc. is calling a virtual special stockholder meeting on February 13, 2026 to vote on several capital structure proposals. The company is seeking authority to implement a reverse stock split of its common stock in a range from 1‑for‑2 to 1‑for‑50, with the exact ratio and timing to be chosen by the board any time up to June 30, 2026. The main goal is to raise the share price to meet Nasdaq’s $1.00 minimum bid requirement and support continued listing on The Nasdaq Capital Market.
Stockholders will also vote on amending the 2024 Equity Incentive Plan to increase the maximum shares available for awards to 10,000,000, up by 8,331,874 shares, which the board says is needed to attract, retain, and motivate employees and directors. As context, the company had 73,536,722 common shares outstanding as of January 13, 2026, and current plan capacity represents about 2% of that total versus about 13.3% if the new limit is fully available. A third proposal would allow adjournment of the meeting to solicit more proxies if needed.